In addition to covalently suppressing mutant KRAS proteins, the degradation of the oncogene KRAS using the proteolysis-targeting chimeras (PROTAC) has emerged as an alternative approach to KRAS-mutant cancers 75. This evidence concerns the gene KRAS and cancer.